These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21035489)

  • 1. Capitalizing on tumor genotyping: towards the design of mutation specific inhibitors of phosphoinsitide-3-kinase.
    Gabelli SB; Duong-Ly KC; Brower ET; Amzel LM
    Adv Enzyme Regul; 2011; 51(1):273-9. PubMed ID: 21035489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane.
    Mandelker D; Gabelli SB; Schmidt-Kittler O; Zhu J; Cheong I; Huang CH; Kinzler KW; Vogelstein B; Amzel LM
    Proc Natl Acad Sci U S A; 2009 Oct; 106(40):16996-7001. PubMed ID: 19805105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis for activation and inhibition of class I phosphoinositide 3-kinases.
    Vadas O; Burke JE; Zhang X; Berndt A; Williams RL
    Sci Signal; 2011 Oct; 4(195):re2. PubMed ID: 22009150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural effects of oncogenic PI3Kα mutations.
    Gabelli SB; Huang CH; Mandelker D; Schmidt-Kittler O; Vogelstein B; Amzel LM
    Curr Top Microbiol Immunol; 2010; 347():43-53. PubMed ID: 20593314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.
    Echeverria I; Liu Y; Gabelli SB; Amzel LM
    FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of PI3Kα by physiological effectors and by oncogenic mutations: structural and dynamic effects.
    Gabelli SB; Echeverria I; Alexander M; Duong-Ly KC; Chaves-Moreira D; Brower ET; Vogelstein B; Amzel LM
    Biophys Rev; 2014 Mar; 6(1):89-95. PubMed ID: 25309634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural comparisons of class I phosphoinositide 3-kinases.
    Amzel LM; Huang CH; Mandelker D; Lengauer C; Gabelli SB; Vogelstein B
    Nat Rev Cancer; 2008 Sep; 8(9):665-9. PubMed ID: 18633356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosteric Activation of PI3Kα Results in Dynamic Access to Catalytically Competent Conformations.
    Chakrabarti M; Gabelli SB; Amzel LM
    Structure; 2020 Apr; 28(4):465-474.e5. PubMed ID: 32049032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit.
    Miled N; Yan Y; Hon WC; Perisic O; Zvelebil M; Inbar Y; Schneidman-Duhovny D; Wolfson HJ; Backer JM; Williams RL
    Science; 2007 Jul; 317(5835):239-42. PubMed ID: 17626883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha ). Functions of lipid kinase-deficient PI3Kalpha in signaling.
    Pirola L; Zvelebil MJ; Bulgarelli-Leva G; Van Obberghen E; Waterfield MD; Wymann MP
    J Biol Chem; 2001 Jun; 276(24):21544-54. PubMed ID: 11278889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docking studies on isoform-specific inhibition of phosphoinositide-3-kinases.
    Sabbah DA; Vennerstrom JL; Zhong H
    J Chem Inf Model; 2010 Oct; 50(10):1887-98. PubMed ID: 20866085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase α that are critical for catalysis and substrate recognition.
    Maheshwari S; Miller MS; O'Meally R; Cole RN; Amzel LM; Gabelli SB
    J Biol Chem; 2017 Aug; 292(33):13541-13550. PubMed ID: 28676499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit.
    Shekar SC; Wu H; Fu Z; Yip SC; Nagajyothi ; Cahill SM; Girvin ME; Backer JM
    J Biol Chem; 2005 Jul; 280(30):27850-5. PubMed ID: 15932879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS).
    Burke JE; Williams RL
    Adv Biol Regul; 2013 Jan; 53(1):97-110. PubMed ID: 23194976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha.
    Sun M; Hillmann P; Hofmann BT; Hart JR; Vogt PK
    Proc Natl Acad Sci U S A; 2010 Aug; 107(35):15547-52. PubMed ID: 20713702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα.
    Liu X; Zhou Q; Hart JR; Xu Y; Yang S; Yang D; Vogt PK; Wang MW
    Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2215621119. PubMed ID: 36343266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase.
    Moon KD; Post CB; Durden DL; Zhou Q; De P; Harrison ML; Geahlen RL
    J Biol Chem; 2005 Jan; 280(2):1543-51. PubMed ID: 15536084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design.
    Chen P; Deng YL; Bergqvist S; Falk MD; Liu W; Timofeevski S; Brooun A
    Protein Sci; 2014 Oct; 23(10):1332-40. PubMed ID: 25043846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.
    Huang CH; Mandelker D; Schmidt-Kittler O; Samuels Y; Velculescu VE; Kinzler KW; Vogelstein B; Gabelli SB; Amzel LM
    Science; 2007 Dec; 318(5857):1744-8. PubMed ID: 18079394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Features that Distinguish Inactive and Active PI3K Lipid Kinases.
    Zhang M; Jang H; Nussinov R
    J Mol Biol; 2020 Nov; 432(22):5849-5859. PubMed ID: 32918948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.